Zymeworks Inc (ZYME)
23.38
+0.28 +1.19%
NYSE
Oct 21, 16:00
23.38
0.00 0.00%
After-Hours: 16:34
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 20.74M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -4.35 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -222.57M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -3.81K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 1.088B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 57.72 |
| PE Ratio | -- |
| Price to Book Value | 3.385 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -52.14M |
| Return on Equity | Upgrade |
View All ZYME News
News
-
WireHeadlineTime (ET)
-
Yahoo10/21 11:16
-
Yahoo10/11 10:00
-
MT Newswires10/07 12:00
-
MT Newswires10/05 10:16
-
Yahoo09/17 13:52
-
Yahoo09/16 11:43
-
Yahoo09/16 05:30
-
MT Newswires09/13 05:29
-
Yahoo09/12 18:49
-
Yahoo09/03 12:23
-
Yahoo08/10 09:38
-
MT Newswires08/05 07:33
-
Yahoo08/04 19:45
-
MT Newswires08/04 16:31
-
Yahoo08/04 16:15
-
MT Newswires08/03 15:49
-
SA Breaking News08/03 08:38
-
Yahoo08/03 08:30
-
Yahoo07/28 15:03
-
MT Newswires07/28 12:34
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/03/2021 | Earnings Results | Q3 2021 Earnings Results |
| 08/04/2021 | Earnings Results | Q2 2021 Earnings Results |
| 05/05/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/05/2021 12:00 EST | AGM | 2020 Annual General Meeting |
| 02/24/2021 | Earnings Results | Q4 2020 Earnings Results |
| 11/03/2020 | Earnings Results | Q3 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.
- URL: http://www.zymeworks.com
- Investor Relations URL: https://ir.zymeworks.com/
- HQ State/Province: British Columbia
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Blend
- Next Earnings Release: Nov. 03, 2021
- Last Earnings Release: Aug. 04, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 23.38 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| ETCHX | Eventide Healthcare & Life Sciences C | 5.23% |
| NGM270 | North Growth Canadian Equity Series F | 3.31% |
| FID5780 | Fidelity Special Situations Series P5 (USD) | 1.76% |
| FID6220 | Fidelity Special Situations Class E5 (USD) | 1.76% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ZYME Tweets Stocktwits
Advertisement
